Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients

被引:4
|
作者
Li, Shuai [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
breast neoplasms; core needle biopsy; surgical sample; Ki-67; change; prognosis; INTERNATIONAL EXPERT CONSENSUS; HER2; STATUS; SURGICAL SPECIMENS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; AMERICAN SOCIETY; KI67; EXPRESSION; WOMEN; INDEX; EXCISION;
D O I
10.3389/fsurg.2022.905575
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background; To investigate the association of Ki-67 change pattern after core needle biopsy (CNB) and prognosis in HR+/HER2- early breast cancer patients. Method: Eligible patients were categorized into three groups: Low group, Elevation group, and High group. Chi-square test and logistic regression analysis were used to compare the clinic-pathological characteristics. Kaplan-Meier method was used to estimate the rates of recurrence-free interval (RFI) and breast cancer-specific survival (BCSS), which were compared via the Log-rank test. Cox proportional hazard analysis was performed to investigate independent prognostic factors. Results: A total of 2,858 patients were included: 1,179 (41.3%), 482 (16.9%), and 1,197 (41.8%) patients were classified into the low, elevation, and high groups, respectively. Age, tumor size, histological grade, lymph-vascular invasion (LVI), and ER level status were associated with Ki-67 change pattern after CNB. With a median follow-up of 53.6 months, the estimated 5-year RFI rates for the low group, elevation, and high groups were 96.4%, 95.3% and 90.9%, respectively (P < 0.001). And 5-year BCSS rates were 99.3%, 98.3% and 96.8%, respectively (P = 0.001). Compared with patients in the low group, patients in the high group had significantly worse RFI (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.16-2.54) in multivariate analysis. Conclusions: Ki-67 change after CNB was associated with prognosis in HR+/HER2- early breast cancer. Patients with Ki-67 high or elevation after CNB had an inferior disease outcome, indicating the necessity of re-evaluating Ki-67 on surgical specimens after CNB.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] De-escalated therapy for HR+/HER2+breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
    Guarneri, V
    Dieci, M., V
    Bisagni, G.
    Frassoldati, A.
    Bianchi, G., V
    De Salvo, G. L.
    Orvieto, E.
    Urso, L.
    Pascual, T.
    Pare, L.
    Galvan, P.
    Ambroggi, M.
    Giorgi, C. A.
    Moretti, G.
    Griguolo, G.
    Vicini, R.
    Prat, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 921 - 926
  • [42] Genistein and enterolactone in relation to Ki-67 expression and HER2 status in postmenopausal breast cancer patients
    Jaskulski, Stefanie
    Jung, Audrey Y.
    Rudolph, Anja
    Johnson, Theron
    Thoene, Kathrin
    Herpel, Esther
    Sinn, Peter
    Chang-Claude, Jenny
    MOLECULAR NUTRITION & FOOD RESEARCH, 2017, 61 (11)
  • [43] Costs of breast cancer recurrence after initial treatment for HR+, HER2-, high-risk early breast cancer: estimates from SEER-Medicare linked data
    Vitko, Alexandra S.
    Martin, Pam
    Zhang, Sheng
    Johnston, Adam
    Ohsfeldt, Robert
    Zheng, Shen
    Liepa, Astra M.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 84 - 96
  • [44] Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence
    Okumura, Y.
    Nishimura, R.
    Nakatsukasa, K.
    Yoshida, A.
    Masuda, N.
    Tanabe, M.
    Shien, T.
    Tanaka, S.
    Arima, N.
    Komoike, Y.
    Taguchi, T.
    Iwase, T.
    Inaji, H.
    Ishitobi, M.
    EJSO, 2015, 41 (04): : 548 - 552
  • [45] Biomarker (ER, PR, Her2 and Ki67) Testing On Core Needle Biopsy Specimens From Primary Breast Cancer - Their Usefulness and Limitations
    Nagaoka, H.
    Takahashi, T.
    Endo, K.
    Sugitani, K.
    Nakagami, K.
    Kim, Y.
    Yoshida, Y.
    Ooki, U.
    Horiguchi, J.
    Takeyoshi, I.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S92 - S92
  • [46] Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2-Breast Cancer: Impact of Tumor Ki67 and ER Status
    Akdag, Goncagul
    Yildirim, Sedat
    Dogan, Akif
    Yasar, Zeynep Yuksel
    Bal, Hamit
    Kinikoglu, Oguzcan
    Oksuz, Sila
    Ozkerim, Ugur
    Tunbekici, Salih
    Yildiz, Hacer Sahika
    Turkoglu, Ezgi
    Alan, Ozkan
    Kokten, Sermin Coban
    Isik, Deniz
    Sever, Ozlem Nuray
    Odabas, Hatice
    Yildirim, Mahmut Emre
    Turan, Nedim
    CHEMOTHERAPY, 2024, 69 (03) : 141 - 149
  • [47] Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
    Michael Crager
    Sameera R. Wijayawardana
    Aaron M. Gruver
    Andrea Blacklock
    Christy Russell
    Frederick L. Baehner
    Francisco Sapunar
    Breast Cancer Research, 24
  • [48] Reliability of core needle biopsy for HER2-low early-stage breast cancer
    Ciniselli, C. M.
    Verderio, P.
    Duroni, V.
    Baili, P.
    Pizzamiglio, S.
    de Braud, F. G.
    Folli, S.
    Depretto, C.
    Scaperrotta, G.
    De Santis, M. C.
    Carnevale, M. G.
    De Marco, C.
    Vingiani, A.
    Pruneri, G.
    Di Cosimo, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [49] Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer
    Jasper, Jacob
    Kantor, Olga
    Dorninici, Laura
    Nakhlis, Faina
    Ogayo, Esther
    Nimbkar, Suniti
    Kurt, Busem Binbogct
    King, Tari
    Mittendorf, Elizabeth
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S101 - S101
  • [50] Risk of Recurrence by Nodal Status and High-Risk Features in Patients with HR+, HER2-, Early Breast Cancer: An Analysis of Real-world Data
    Grimes, B.
    Tolaney, S. M.
    Sammons, S.
    Cortes, J.
    Liepa, A. M.
    Sugihara, T.
    Cui, Z. Lin
    Gathirua-Mwangi, W.
    Shahir, A.
    Monaco, M.
    Neven, P.
    Johnston, S.
    BREAST, 2025, 80